Reason for request
Inclusion
Clinical Benefit
| Substantial |
Substantial actual benefit |
Clinical Added Value
| important |
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation. |
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
pmS1ACH2SwyTyYSL
